Publications

Export 2578 results:
Sort by: Author [ Title  (Desc)] Type Year
A [B] C D E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
B
Sattar, A. A. M., Bed Morphological Changes of the Nile River DS Major Barrages, , Berlin, Heidelberg, Springer Berlin Heidelberg, pp. 1–16, Submitted. Abstract
n/a
Sewify, G. A. M. A. L. H., Y. Y. Ibrahim, and M. S. El-Deen, "Beauveria bassiana (Balsamo), a Potential Mycopesticide for Efficient Control of the Honey Bee Ectoparasitic Mite, Varroa destructor Anderson and Trueman", Egyptian Journal of Biological Pest Control, vol. 25, issue 2, pp. 333-337, 2015. 55_swefy_2285928.pdf
Stino, R. G., E. S. Hegazy, T. A. Yehia, and A. A. Hegazy, "Bearing potential, fruit growth and quality of Anna apples in relation to bud positions and pollination regimes", Egyptian Journal of Horticulture,(Egypt), 2002. Abstract
n/a
E.S.Hegazi, T. A. Yehia, R. G. Stino, and A. A. Hegazy, "Bearing potential, fruit growth and quality of Anna apple in relation to bud position and pollination regimes. ", Egyptian Journal of Horticulture, vol. 28, issue 3., 2001.
Hassanien, A., A. S. Elkader, A. B. Gershman, and K. M. Wong, "Beamspace preprocessing with an improved robustness against out-of-sector sources using second-order cone programming", Sensor Array and Multichannel Signal Processing Workshop Proceedings, 2004: IEEE, pp. 347–351, 2004. Abstract
n/a
Abdou, S., and M. S. Scordilis, "Beam Search Pruning in Speech Recognition Using a Posterior Probabiliy based Confidence Measure", Speech Communication, vol. 42, no. 3, pp. 409–428, 2003. Abstract
n/a
Abdou, S., and M. S. Scordilis, "Beam search pruning in speech recognition using a posterior probability-based confidence measure", Speech Communication, vol. 42, no. 3: Elsevier, pp. 409–428, 2004. Abstract
n/a
Emara, K. H. S., Be my friend, , Cairo, General Egyptian book organization, 2002.
Elbogdady, M., S. Shamaa, E. Azmy, T. Abozeid, M. AbdElmoety, and Z. Emara, "BCR-ABL1/ABL reduction ratio superiority over EMR and halving time as a predictor for outcome in Egyptian chronic phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.", 24th Congress of the European Hematology Association, June 2019: Abst. PB1927, Amsterdam, The Netherlands , HemaSphere 2019, 3 (S1), pp. 876, 2019. bcr-abl1abl_reduction_ratio_superiority_over_emr_and_halving_time...._eha_library._elbogdady_m._may_16_2019_267896.pdf
Oing, C., P. Tennstedt, R. Simon, J. Volquardsen, K. Borgmann, C. Bokemeyer, C. Petersen, E. Dikomey, K. Rothkamm, and W. Y. Mansour, "BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.", Cancer letters, vol. 423, pp. 60-70, 2018 06 01. Abstract

Here we report that BCL2 blocks DNA double strand break (DSB) repair via nonhomologous end-joining (NHEJ), through sequestration of KU80 protein outside the nucleus. We find that this effect is associated with a repair switch to the error-prone PARP1-dependent end-joining (PARP1-EJ). We present in-vitro proof-of-concept for therapeutic targeting of this switch using PARP inhibitor to specifically enhance the radiosensitivity of BCL2-overexpressing cells. Given its erroneous behavior, PARP1-EJ might allow for the accumulation of genetic alterations and tumor progression. Consistently, we report an inverse correlation between BCL2 expression and biochemical recurrence-free survival of 10.259 prostate cancer (PCa) patients who underwent primary radical-prostatectomy for localized disease. Further, we evaluated retrospectively the impact of BCL2 expression on clinical outcome of 1.426 PCa patients, who had been given salvage radiotherapy at relapse after radical prostatectomy. In line with its role in blocking NHEJ, BCL2 over-expressers showed significantly better response to salvage radiotherapy compared to low-expressers. Collectively, our findings identify BCL2 status in PCa as a putative predictor of (i) radiotherapy response and (ii) response to treatment with PARP inhibitor olaparib as a radiosensitizing agent.

Fouad, H., and A. Eldemery, "Bcl2 and c-erbB-3 as Prognostic Markers of Hepatocellular Carcinoma", Bulletin of Egyptian Society for Physiological Sciences, vol. 30, no. 1: Egyptian Society for Physiological Sciences, pp. 301–310, 2010. Abstract
n/a
Ismail, I. H., A. Dronyk, X. Hu, M. J. Hendzel, and A. R. Shaw, "BCL10 is recruited to sites of DNA damage to facilitate DNA double-strand break repair.", Cell cycle (Georgetown, Tex.), vol. 15, issue 1, pp. 84-94, 2016 Jan 2. Abstract

Recent studies have found BCL10 can localize to the nucleus and that this is linked to tumor aggression and poorer prognosis. These studies suggest that BCL10 localization plays a novel role in the nucleus that may contribute to cellular transformation and carcinogenesis. In this study, we show that BCL10 functions as part of the DNA damage response (DDR). We found that BCL10 facilitates the rapid recruitment of RPA, BRCA1 and RAD51 to sites of DNA damage. Furthermore, we also found that ATM phosphorylates BCL10 in response to DNA damage. Functionally, BCL10 promoted DNA double-strand breaks repair, enhancing cell survival after DNA damage. Taken together our results suggest a novel role for BCL10 in the repair of DNA lesions.

Mossallam, G., A. M. Kamel, S. S. Meshaal, D. A. Labib, R. M. Abdelfattah, M. A. Samra, M. M. Sherif, and O. A. Gohar, "Bcl-xL expression as a potential prognostic parameter in Chronic myeloid Leukemia.", The Journal of the Egyptian Society of Haematology and Research, vol. 6, issue 10, pp. 17-22, 2010.
Kamel, A. M., G. I. Mossallam, S. S. Meshaal, D. Labib, R. Abdelfattah, M. A. Samra, M. Sherif, and O. Goher, "BCL-XL Expression as a Potential Prognostic Parameter In Chronic Myeloid Leukemia.", Haematologica, vol. 98, issue S1, pp. 548: Abst. B1348, 2013.
AM, K., M. G, M. SS, L. D. A, A. RM, S. MA, and S. MM, "Bcl-xL expression as a potential prognostic parameter in chronic myeloid leukemia", CML–ESH-iCMLf 15th International Conference on Chronic Myeloid Leukemia: Biology and Therapy, Estoril, Portugal, 2011.
El-Shakankiry, N. H., G. M. El-Sayed, S. El-Maghraby, and M. M. Moneer, "Bcl-2 protein expression in egyptian acute myeloid leukemia", Journal of the Egyptian National Cancer Institute, vol. 21, issue 1, pp. 71 - 76, 2009. Abstract

OBJECTIVE: The primary cause of treatment failure in acute myeloid leukemia (AML) is the emergence of both resistant disease and early relapse. The bcl-2 gene encodes a 26-kDa protein that promotes cell survival by blocking programmed cell death (apoptosis). In the present study, bcl-2 protein expression was evaluated in newly diagnosed AML patients and correlated with the induction of remission and overall survival (OS), in an attempt to define patients who might benefit from modified therapeutic strategies.PATIENTS AND METHODS: Pretreatment cellular bcl-2 protein expression was measured in bone marrow samples obtained from 68 patients of newly diagnosed acute myeloid leukemia and 10 healthy controls by western blotting.
RESULTS: The mean bcl-2 protein expression was significantly higher in patients (0.686+/-0.592) compared to controls (0.313+/-0.016) (p=0.002). The overall survival for patients with mean bcl-2 expression of less, and more than or equal to 0.315, was 67% and 56%, respectively, with no significant difference between the two groups (p=0.86).
CONCLUSION: Even though we did not observe a significant difference in overall survival between patients with high and low levels of bcl-2, modulation of this protein might still be considered as an option for enhancing the effectiveness of conventional chemotherapy.
KEY WORDS: Acute myeloid leukemia (AML) - Bcl-2 - prognosis - Western blot.

D, M., E. - E. N, E. - T. AM, and B. DA, "Bcl-2 expression in mycosis fungoides before and after PUVA therapy", Photodermatol Photoimmunol Photomed, vol. 26, issue 2, pp. 107-9, 2010. Abstract

PUVA is the first therapeutic choice in early stages of mycosis fungoides (MF). In this study the effect of PUVA on bcl-2 expression in MF was assessed in 15 patients (three stage Ia and 12 stage Ib) and 10 controls. Two biopsies were taken from each patient before and after 24 sessions of PUVA therapy. Histopathological assessment and immunohistochemical staining for bcl-2 was performed and showed positive bcl-2 staining of lymphocytes in 53% of MF cases (8/15) before PUVA, with no statistically significant difference in the bcl-2 level before and after PUVA therapy (P value 0.3). A statistically significant difference was found in the bcl-2 level between control samples and MF patients’ biopsies before (P value 0.02) and after PUVA therapy (P value 0.011). In conclusion, a lack of decline in the bcl-2 level and the absence of clinical or histopathological correlation with the bcl-2 level before and after PUVA therapy in MF patients suggest that PUVA-induced apoptosis in MF cases may occur through
pathways other than bcl-2 inhibition.

Weshahy, H., D. Mahgoub, N. El-Eishy, A. M. El-Tawdy, D. A. Bassiouny, N. Hunter, and A. Hindawi, "Bcl-2 expression in mycosis fungoides before and after PUVA therapy", Photodermatology, photoimmunology & photomedicine, vol. 26, no. 2: Wiley Online Library, pp. 107–109, 2010. Abstract
n/a
Weshahy, H., D. Mahgoub, N. El-Eishy, A. M. El-Tawdy, D. A. Bassiouny, N. Hunter, and A. Hindawi, "Bcl-2 expression in mycosis fungoides before and after PUVA therapy", Photodermatology, photoimmunology & photomedicine, vol. 26, no. 2: Wiley Online Library, pp. 107–109, 2010. Abstract
n/a
Weshahy, H., D. Mahgoub, N. El-Eishy, A. M. El-Tawdy, D. A. Bassiouny, N. Hunter, and A. Hindawi, "Bcl-2 expression in mycosis fungoides before and after PUVA therapy", Photodermatology, photoimmunology & photomedicine, vol. 26, no. 2: Wiley Online Library, pp. 107–109, 2010. Abstract
n/a
Mahgoub, D., N. El-Eishy, A. M. El-Tawdy, and D. A. Bassiouny, "Bcl-2 expression in mycosis fungoides before and after PUVA therapy", Photodermatol Photoimmunol Photomed, vol. 26, no. 2, 2010. Abstract
n/a